Lv35
280 积分 2025-01-07 加入
Intrinsic and Extrinsic Limitations to the Design and Optimization of Inhibitors of Lipid Peroxidation and Associated Cell Death
2天前
已完结
Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery
8天前
已完结
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intramuscular Cabotegravir and Rilpivirine in Healthy Adult Subjects
8天前
已关闭
https://doi.org/10.1016/j.ejps.2024.106718
8天前
已完结
Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA Approvals
9天前
已完结
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes
9天前
已完结
A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials
9天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
9天前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
9天前
已完结
Clinical Delivery of Circular RNA: Lessons Learned from RNA Drug Development
9天前
已完结
皖公网安备34019202002308
